A novel chenodeoxycholic acid-verticinone ester induces apoptosis and cell cycle arrest in HepG2 cells.
In this study, the in vitro antitumor activity of chenodeoxycholic acid-verticinone ester (CDCA-Ver), a novel compound and its underlying mechanisms were evaluated. Results showed that CDCA-Ver significantly inhibited HepG2 cell viability in a both dose- and time-dependent manner, moreover CDCA-Ver induced apoptotic cell death and G(0)/G(1) cell cycle arrest in HepG2 cells. ROS generation, loss of balance of Bax/Bcl-2 ratio, loss of mitochondrial transmembrane potential, activation of caspases and elevation of intracellular free Ca(2+) concentration were involved in the CDCA-Ver induced apoptosis pathway in HepG2 cells. We concluded that CDCA-Ver may be a potential candidate for the therapy of cancer.